Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin.

Abstract

CHPPC with docetaxel following cytoreductive surgery for early recurrent or persistent peritoneal carcinomatosis from gynaecological malignancies seems feasible and might have a positive impact on survival. The outcome seems to be superior to that of CHPPC with other drugs.